Description
17-DMAG is an inhibitor of HSP90 that exhibits neuroprotective, anticancer chemotherapeutic, and antiviral activities. In animal models of Machado-Joseph disease, 17-DMAG increases levels of beclin-1 and LC3-11, inducing autophagy and improving motor dysfunction. In neuroblastoma cells, this compound exerts effects on anaplastic lymphoma kinase (ALK) and N-Myc, inducing cell cycle arrest and apoptosis. Additionally, 17-DMAG inhibits cell growth and induces apoptosis in adult T-cell leukemia (ATL) cells. In animal models with ATL xenografts, 17-DMAG inhibits metastasis and improves survival rates. 17-DMAG also prevents viral production by human T-lymphocytic virus type-1. In separate models, 17-DMAG decreases expression of conserved herpesvirus protein kinases and suppresses viral growth.
References
Silva-Fernandes A, Duarte-Silva S, Neves-Carvalho A, et al. Chronic Treatment with 17-DMAG Improves Balance and Coordination in A New Mouse Model of Machado-Joseph Disease. Neurotherapeutics. 2014 Jan 30. [Epub ahead of print]. PMID: 24477711.
Yi B, Yang J, Wang L. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line. Tumour Biol. 2013 Nov 30. [Epub ahead of print]. PMID: 24293393.
Sun X, Bristol JA, Iwahori S, et al. Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells. J Virol. 2013 Sep;87(18):10126-38. PMID: 23843639.
Ikebe E, Kawaguchi A, Tezuka K, et al. Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice. Blood Cancer J. 2013 Aug 16;3:e132. PMID: 23955587.
